Loading clinical trials...
Loading clinical trials...
The primary objective of this study is to evaluate the safety and tolerability of MEDI-551 in Japanese patients with relapsed or refractory advanced B-cell malignancies.
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
AstraZeneca
Collaborators
NCT06510699 · Fungal Infection, Haematological Malignancy, and more
NCT05873205 · Blood Cancer, Refractory Immune Cytopenias
NCT07148180 · Acute Myeloid Leukaemia (AML), Leukemia, and more
NCT07305090 · Blood Cancer
NCT06455592 · Child, Only, Blood Cancer, and more
Research Site
Fukuoka
Research Site
Isehara-shi
Research Site
Nagoya
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions